Literature DB >> 2155952

Natural cell-mediated cytotoxicity against various target cells in patients with epidermodysplasia verruciformis.

S Majewski1, J Malejczyk, S Jablonska, J Misiewicz, L Rudnicka, S Obalek, G Orth.   

Abstract

Natural cell-mediated cytotoxicity of peripheral blood mononuclear cells was studied in eight patients with epidermodysplasia verruciformis induced by human papillomaviruses specific for epidermodysplasia verruciformis and in five patients with epidermodysplasia verruciformis-induced exclusively by human papillomavirus type 3. Nine patients with various cutaneous warts and 25 age- and sex-matched healthy persons were control subjects. Natural cell-mediated cytotoxicity against both K-562 erythroleukemic and Sk-v cells was in the normal range in patients with epidermodysplasia verruciformis induced by epidermodysplasia verruciformis-specific human papillomaviruses and in patients with cutaneous warts. The lysis of both targets, however, was significantly decreased in patients with the form of epidermodysplasia verruciformis associated with human papillomavirus type 3. Experiments with normal keratinocytes and with keratinocytes isolated from a malignant lesion bearing human papillomavirus type 5 genomes showed that the latter were susceptible to lysis by the peripheral blood mononuclear cells of healthy persons and of patients with cutaneous warts. Lysis of keratinocytes in epidermodysplasia verruciformis, however, was strongly reduced in patients with epidermodysplasia verruciformis induced by specific human papillomaviruses. This reduction was not associated with a decrease in anti-K-562 natural cell-mediated cytotoxicity. Our results suggest that in patients with epidermodysplasia verruciformis induced by disease-specific human papillomaviruses, there is reduced natural cell-mediated cytotoxicity against epidermodysplasia verruciformis keratinocytes.

Entities:  

Mesh:

Year:  1990        PMID: 2155952     DOI: 10.1016/0190-9622(90)70058-p

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts.

Authors:  K R Beutner; S K Tyring; K F Trofatter; J M Douglas; S Spruance; M L Owens; T L Fox; A J Hougham; K A Schmitt
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 3.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

4.  EVER2 deficiency is associated with mild T-cell abnormalities.

Authors:  Amandine Crequer; Capucine Picard; Vincent Pedergnana; Annick Lim; Shen-Ying Zhang; Laurent Abel; Slawomir Majewski; Jean-Laurent Casanova; Stefania Jablonska; Gerard Orth; Emmanuelle Jouanguy
Journal:  J Clin Immunol       Date:  2012-08-19       Impact factor: 8.317

Review 5.  Multiple metachronous skin squamous cell carcinomas and epidermodysplasia verruciformis in the head region: a human papilloma virus-associated disease.

Authors:  B P Weber; G Fierlbeck; H G Kempf
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

6.  The transmembrane channel-like protein family and human papillomaviruses: Insights into epidermodysplasia verruciformis and progression to squamous cell carcinoma.

Authors:  Jaime S Horton; Alexander J Stokes
Journal:  Oncoimmunology       Date:  2014-04-15       Impact factor: 8.110

7.  HLA-C -35kb expression SNP is associated with differential control of β-HPV infection in squamous cell carcinoma cases and controls.

Authors:  Karin A Vineretsky; Margaret R Karagas; Jacquelyn K Kuriger-Laber; Tim Waterboer; Michael Pawlita; Heather H Nelson
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.